Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 10Osteosarcoma 5Bone Neoplasms 5Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Liposarcoma 3Leiomyosarcoma 3Sarcoma, Synovial 2Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Nerve Sheath Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Histiocytoma, Malignant Fibrous 2Gliosarcoma 2Gastrointestinal Stromal Tumors 2Fibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Clear Cell 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neurofibromatoses × Sarcoma × Clear all
NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡